KDM5A and neoplasm: More interestingly, high KDM5A/B expression characterizes a small subpopulation of slowly cycling, tumor-initiating cells that are intrinsically resistant to a wide variety of cancer therapeutics, including both cytotoxic (e.g. Cis-platinum) and targeted agents (tyrosine kinase inhibitors, Bortezomib, B-raf inhibitors) [200–202].